The FDA’s drug approval database lists an oral solution of Levetiracetam (100 mg/mL) under product number 001. The product is marked as discontinued and is not a reference drug.
Since the original approval (submission 1, ORIG) on 17 Oct 2011, the agency has approved a series of labeling supplement (SUPPL) submissions for this product. Approved submissions include numbers 1 (03 Nov 2014), 3 (12 Mar 2013), 6 (03 Nov 2014), 9 (24 Dec 2015), 10 (24 Dec 2015), 13 (16 Mar 2023), 14 (16 Mar 2023), 15 (date incomplete), 18 (16 Mar 2023), 20 (16 Mar 2023), 22 (24 Oct 2023), and 23 (22 Nov 2024). All listed submissions have a status of AP (Approved) and pertain to labeling updates.
Actualizaciones regulatorias4 sept 2026•1 min de lectura
FDA Approves Multiple Labeling Updates for Levetiracetam Oral Solution
The FDA has approved several labeling supplement submissions for the discontinued oral solution Levetiracetam (100 mg/mL) spanning from 2011 to 2024.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración